Study of Viral Transduction of Human Auditory Sensory Cells for the Development of Gene Therapy
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Institut Pasteur
- Trial code
- NCT03996824
- Record updated
- 19 September 2024
- Original description
Gene therapy is a promising strategy to treat hearing loss and vestibular disorders, and Associated adenovirus (AAV) is shown as a good viral vector for inner ear therapy in animal models.Read full original descriptionShow less
Gene therapy is a promising strategy to treat hearing loss and vestibular disorders, and Associated adenovirus (AAV) is shown as a good viral vector for inner ear therapy in animal models.
This study aims to study in vitro viral transduction of AAV in human inner ear cells, collected during non-conservative surgeries for vestibular schwannoma.
Inclusion: Patient ≥ 18 years old; Operative indication for a non-conservative resection of vestibular schwannoma, decided by the surgeon in accordance with the patient; Informed consent obtained; Patients with a french social protection (AME excluded).
Exclusion: Intravestibular or intra-cochlear extension of the tumor; Pregnant woman; Patient with administrative control; Medical contra-indication.